<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33326235</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>ACS chemical neuroscience</Title><ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation></Journal><ArticleTitle>Exposure of &#x3b2;6/&#x3b2;7-Loop in Zn/Cu Superoxide Dismutase (SOD1) Is Coupled to Metal Loss and Is Transiently Reversible During Misfolding.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>62</EndPage><MedlinePgn>49-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.0c00524</ELocationID><Abstract><AbstractText>Upon losing its structural integrity (misfolding), SOD1 acquires neurotoxic properties to become a pathogenic protein in ALS, a neurodegenerative disease targeting motor neurons; understanding the mechanism of misfolding may enable new treatment strategies for ALS. Here, we reported a monoclonal antibody, SE21, targeting the &#x3b2;6/&#x3b2;7-loop region of SOD1. The exposure of this region is coupled to metal loss and is entirely reversible during the early stages of misfolding. By using SE21 mAb, we demonstrated that, in apo-SOD1 incubated under the misfolding-promoting conditions, the reversible phase, during which SOD1 is capable of restoring its nativelike conformation in the presence of metals, is followed by an irreversible structural transition, autocatalytic in nature, which takes place prior to the onset of SOD1 aggregation and results in the formation of atypical apo-SOD1 that is unable to bind metals. The reversible phase defines a window of opportunity for pharmacological intervention using metal mimetics that stabilize SOD1 structure in its nativelike conformation to attenuate the spreading of the misfolding signal and disease progression by preventing the exposure of pathogenic SOD1 epitopes. Phenotypically similar apo-SOD1 species with impaired metal binding properties may also be produced via oxidation of Cys<sup>111</sup>, underscoring the diversity of SOD1 misfolding pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakavayev</LastName><ForeName>Shamchal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argueti</LastName><ForeName>Shirel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Sciences and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatachalam</LastName><ForeName>Nachiyappan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yehezkel</LastName><ForeName>Galit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Faculty of Natural Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavsky</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Sciences and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barak</LastName><ForeName>Zeev</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Faculty of Natural Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelson</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8289-7653</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, Faculty of Health Sciences and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engel</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5916-5190</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Neurosci</MedlineTA><NlmUniqueID>101525337</NlmUniqueID><ISSNLinking>1948-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Lou Gehrig disease</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">Zn/Cu superoxide dismutase</Keyword><Keyword MajorTopicYN="N">copper cofactor</Keyword><Keyword MajorTopicYN="N">fALS mutants</Keyword><Keyword MajorTopicYN="N">hydrogen peroxide</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">oxidation</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">protein misfolding</Keyword><Keyword MajorTopicYN="N">sulfenic acid</Keyword><Keyword MajorTopicYN="N">sulfinic acid</Keyword><Keyword MajorTopicYN="N">sulfonic acid</Keyword><Keyword MajorTopicYN="N">zinc cofactors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>16</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33326235</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.0c00524</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>